Citius Oncology, Inc. SEC filings CTOR
Citius Oncology, Inc. has 268 filings in SEC EDGAR's recent list, going back to May 19, 2021. Its latest annual report, Form ARS, was filed on Aug 26, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 5, 2026 | — |
| CORRESP | Letter to the SEC | Jun 3, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2026 | — |
| EFFECT | Filing | Mar 2, 2026 | — |
| EFFECT | Filing | Jan 12, 2026 | — |
| CORRESP | Letter to the SEC | Jan 9, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2026 | — |
| EFFECT | Filing | Sep 4, 2025 | — |
| CORRESP | Letter to the SEC | Sep 2, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2025 | — |
| DRS | Filing | Aug 20, 2025 | — |
| EFFECT | Filing | Jul 16, 2025 | — |
| CORRESP | Letter to the SEC | Jul 15, 2025 | — |
| UPLOAD | Letter from the SEC | May 1, 2025 | — |
| DRS | Filing | Apr 28, 2025 | — |
| DEFA14C | Definitive additional materials | Feb 24, 2025 | — |
| 25-NSE | Delisting notice | Aug 13, 2024 | — |
| 425 | Filing | Jul 19, 2024 | — |
| SEC STAFF LETTER | Filing | Jul 12, 2024 | — |
| EFFECT | Filing | Jul 12, 2024 | — |
| CORRESP | Letter to the SEC | Jul 11, 2024 | — |
| 425 | Filing | Jun 18, 2024 | — |
| CORRESP | Letter to the SEC | Jun 17, 2024 | — |
| 425 | Filing | Jun 6, 2024 | — |
| UPLOAD | Letter from the SEC | May 17, 2024 | — |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| CORRESP | Letter to the SEC | May 3, 2024 | — |
| 425 | Filing | Apr 29, 2024 | — |
| NT 10-K | Filing | Apr 2, 2024 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Feb 13, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2024 | — |
| SEC STAFF LETTER | Filing | Dec 14, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2023 | — |
| NT 10-Q | Filing | Nov 14, 2023 | Sep 30, 2023 |
| 425 | Filing | Oct 24, 2023 | — |
| NT 10-Q | Filing | Aug 15, 2023 | Jun 30, 2023 |
| NT 10-K | Filing | Mar 31, 2023 | Dec 31, 2022 |
| EFFECT | Filing | Oct 13, 2022 | — |
| CERT | Filing | Oct 13, 2022 | — |
| 8-A12B | Filing | Oct 13, 2022 | — |
| CORRESP | Letter to the SEC | Oct 11, 2022 | — |
| CORRESP | Letter to the SEC | Oct 11, 2022 | — |
| CORRESP | Letter to the SEC | Jul 29, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2022 | — |
| CORRESP | Letter to the SEC | May 12, 2022 | — |
| CORRESP | Letter to the SEC | May 12, 2022 | — |
| CORRESP | Letter to the SEC | May 11, 2022 | — |
| CORRESP | Letter to the SEC | May 11, 2022 | — |
| CORRESP | Letter to the SEC | Mar 8, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 14, 2021 | — |
| CORRESP | Letter to the SEC | Aug 20, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2021 | — |
| CORRESP | Letter to the SEC | Jun 29, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2021 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTOR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Cranford, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1851484
- Former names
- TenX Keane Acquisition (until Aug 5, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.